TABLE 2.
Proportions of patients with PASI 75, PASI 90, PASI 100, and PGA 0/1 at base study week 64 and extension study week 192
| Responders | Base study week 64 | Extension study week 192 | ||
|---|---|---|---|---|
|
TIL 100 mg a n = 54 |
n = 57 |
TIL 100 mg n = 44 |
TIL 200 mg n = 58 |
|
| PASI 75, n (%) | 48 (88.9) | 42 (73.7) | 35 (79.5) | 44 (75.9) |
| PASI 90, n (%) | 30 (55.6) | 26 (45.6) | 21 (47.7) | 26 (44.8) |
| PASI 100, n (%) | 18 (33.3) | 10 (17.5) | 11 (25.0) | 9 (15.5) |
| PGA 0/1, n (%) | 42 (77.8) | 37 (64.9) | 26 (59.1) | 36 (62.1) |
Abbreviations: PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment; TIL, tildrakizumab.
Includes patients with a partial response at week 28 who continued to receive the same dose.
Excludes patients with a partial response at week 28 in the TIL 100 mg group who were rerandomized to TIL 200 mg. These patients were omitted because they were disproportionately rerandomized to TIL 200 mg versus TIL 100 mg. The response rates including these patients (n = 66 patients total receiving TIL 200 mg at week 64) were PASI 75, 68.2%; PASI 90, 39.4%; PASI 100, 15.2%; PGA 0/1, 59.1%.